Tamtam Try Tamtam free
Baxter International Inc. logo

Baxter International Inc. account plan

Patient-focused healthcare technology

At a glance

Baxter International is a Deerfield, Illinois medtech group with FY2025 net sales of $11.24 billion and about 37,500 employees.

Baxter International Inc. sells sterile IV solutions, infusion systems, parenteral nutrition, surgical hemostats and sealants, specialty injectables, inhaled anesthetics, smart beds, patient monitoring and respiratory devices. Its customers are hospitals, nursing homes, ambulatory surgery centers, doctors' offices and patients at home, reached through a direct sales force, distributors and U.S. group purchasing organizations. It manufactures in over 20 countries and sells in over 100, with approximately 37,500 employees. FY2025 net sales were $11.24 billion (+6% reported, +3% operational), with a net loss attributable to Baxter of $(957) million after $2.07 billion of special items. The Kidney Care business (now Vantive) was sold to Carlyle on January 31, 2025.

Business units

Strategic priorities

Stabilize the business
Under CEO Andrew Hider the first phase is stabilizing operations: in Care & Connectivity Solutions an on-time shipment metric improved 8% year over year, and an Advanced Surgery quality measure improved by nearly 20%.
Deleverage to about 3x by end-2026
Baxter targets a net leverage of approximately 3.0x by the end of 2026 while keeping an investment grade rating; the dividend was cut to $0.01 per share and no buybacks are made during deleveraging.
Continuous improvement through Baxter GPS
The Baxter Growth and Performance system, launched in October 2025, delivered more than 700 initiatives in 2026, with more than 200 in flight and about 350 planned, alongside automation, digitization and the exploration of AI.
Decentralized, simpler organization
Baxter has moved to independent P&Ls and implemented a new two-segment operating model in Q2 2026, removing managerial layers and keeping some shared corporate costs unallocated.
Innovation in connected care
Priorities include connected care offerings such as Connex 360 monitoring, the Dynamo Series Smart Stretcher, and the IQX platform linking the Spectrum LVP and Novum syringe.
Portfolio buckets and tuck-in M&A
The portfolio is split into invest-and-grow (ambulatory cardiac monitoring with Bardy, Advanced Surgery), sustain (IV solutions) and fix; future moves are expected to be more pruning, and tuck-in acquisitions are judged on strategic rationale, market attractiveness, integration and financial return.

Latest results

In Q3 2026 net sales were $2,976 million vs $2,835 million, +5% reported and +5% organic, with U.S. sales of $1,595 million and International $1,381 million. Net income attributable to Baxter was $294 million, or $0.57 per diluted share, against $(46) million a year earlier, helped by a $253 million gain on early debt extinguishment; adjusted EPS was $0.58. Free cash flow was $448 million in the quarter and $705 million year-to-date. Over nine months net sales were $8,637 million, +4% reported. Baxter raised its FY2026 outlook to reported sales growth of 4% to 5%, organic growth of 3% to 4% and adjusted EPS of $2.05 to $2.15.

Investments and deals

Kidney Care divestment
The Kidney Care business was sold to Carlyle on January 31, 2025 for an aggregate $3.80 billion; about $3.2 billion of after-tax proceeds were used to repay debt.
Debt reduction and tender offer
Total debt repayments in 2025 were $5.49 billion; in September 2026 a $600 million cash tender offer retired $864 million of debt, according to the earnings release.
Capital expenditure
Capital expenditures were $513 million in FY2025 and $363 million over the first nine months of 2026, focused on production efficiency, quality systems and capacity.
Restructuring and cephalosporin exit
2026 restructuring targets the post-Kidney Care cost structure ($79 million of employee termination costs over nine months) and the end of cephalosporin production at the Round Lake, Illinois plant ($39 million).

Challenges and risks

Novum LVP recalls
Class I recalls from 2025 led to about $105 million of charges in 2025, and the U.S./Canada ship and install hold continues with no meaningful Novum LVP sales expected meanwhile.
FDA Warning Letter at Round Lake
An FDA inspection in March-April 2026 led to an OAI classification and a Warning Letter in September 2026; Baxter is implementing corrective actions.
Margin pressure and Front Line Care impairments
FY2025 gross margin fell to 30.1% from 37.5%, and Front Line Care took a $485 million goodwill impairment in Q4 2025 plus a $290 million Welch Allyn trade name impairment.
Tariffs and inflation
Section 122 duties and Section 301 tariffs are still expected to weigh on results, and the CFO expects higher inflation led by salaries, then electronics and materials, in 2027.
Kidney Care dis-synergies
Vantive TSA services end by the end of January 2027, leaving stranded costs, and the risk factors name dis-synergies from the reduced size of the company.

What leadership says

“We delivered a strong third quarter, with growth across all segments and divisions globally”

Andrew Hider, President and CEO · Baxter reports third-quarter 2026 results, earnings release, October 29, 2026

“further evidence that our turnaround is gaining traction”

Andrew Hider, President and CEO · Baxter Q3 2026 earnings call, October 29, 2026

“If you can measure it, you can manage it. If you can manage it, you can improve it.”

Andrew Hider, President and CEO · Wells Fargo 21st Annual Healthcare Conference fireside chat, September 9, 2026

“I have been pleased with the progress, but we are not yet happy with the results yet”

Andrew Hider, President and CEO · Wells Fargo 21st Annual Healthcare Conference fireside chat, September 9, 2026

Where a supplier can help

IT and finance cost reduction
The CFO named IT (a large number of applications) and finance costs as savings opportunities to offset inflation and Kidney Care dis-synergies; application rationalization and finance automation suppliers fit that challenge.
Quality and regulatory remediation
The Round Lake Warning Letter and the Novum LVP recalls create demand for quality systems, validation and regulatory consulting support tied to the stabilization priority.
Manufacturing productivity under Baxter GPS
With hundreds of continuous improvement initiatives and plant teams using AI, automation, digitization and lean tooling providers can support the continuous improvement priority and the capex focus on production efficiency.
Supply chain resilience
Tariffs, a contract manufacturer's supply problems in injectables and single-source supplier risk make alternative sourcing, supplier quality and tariff mitigation services relevant.
Connected care technology partners
The invest-and-grow push in cardiac monitoring and connected care (Connex 360, IQX) opens room for software, data and component partners that help gather data across the care workflow.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Baxter International Inc.?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Baxter International Inc.

What does Baxter International do?

Baxter makes sterile IV solutions, infusion systems, surgical hemostats and sealants, specialty injectables, smart beds, patient monitoring and respiratory devices for hospitals, surgery centers, nursing homes and home patients in over 100 countries.

What is Baxter's revenue?

FY2025 net sales were $11.24 billion, +6% reported. For FY2026 Baxter guides to reported sales growth of 4% to 5%, after Q3 2026 sales of $2,976 million.

How many employees does Baxter have?

Approximately 37,500 employees, about 15,100 in the U.S. and 22,400 outside, according to the FY2025 10-K.

Who leads Baxter?

Andrew Hider has been President and CEO since 2025; John Rogers joined as CFO on October 1, 2026.

What is Baxter's strategy?

Stabilize the business, reduce net leverage to approximately 3x by end-2026, drive continuous improvement through Baxter GPS and then move into capital allocation, including tuck-in acquisitions.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)